Changing Landscape of Treatment Options for Multiple Myeloma

/ Print /
| ShareMore
/ Text Size +
9/29/20 1:00 pm EST
Virtual Webinar
United States

Melanoma Cancernet Banner

This webinar is jointly provided by CancerNet, LLC. and Amedo, LLC.

cancernet Logo 2017                      amedcologo    

This activity is supported in part by an independent education grant from Amgen Inc. and, Sanofi Genzyme.

Webinar Overview:

This activity will cover topics on the diagnosis, treatment, and management of patients with multiple myeloma. Upon completion of this activity, participants should be better able to:

  • Outline the classification and treatment of smoldering multiple myeloma (MM)
  • Develop individualized treatment plans for MM patients based on cytogenetic and genomic data
  • Identify the benefits and risks of frontline therapy for MM
  • Customize the consolidation and maintenance therapy options for MM
  • Summarize the role of sequencing therapies in relapsed MM
  • Recognize the role of geriatric assessments and their use in MM
  • Assess the potential of CAR-T cell and future therapies in MM

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, physician assistants, nurse practitioners, nurses involved in the treatment of patients with multiple myeloma.

Date and Time:

This webinar will be held on:

  • Saturday, September 19, 2020 10:00 AM – 1:15 PM EDT
  • Tuesday, September 29, 2020 1:00 PM – 4:15 PM EDT


Keith Stewart, MBChB, MRCP
Vice President
Cancer and Director of the Princess Margaret Cancer Program
UHN, Regional Vice-President
Toronto Central South Regional Cancer Program
Ontario Health, Toranto, Canada

Joseph Mikhael, MD
Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen)
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Scottsdale, AZ

Amrita Krishnan, MD
Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
Duarte, CA

Ajai Chari, MD
Professor of Medicine
Director of Clinical Research in the Multiple Myeloma Program
Associate Director of Clinical Research
Mt Sinai Cancer Clinical Trials Office
Mount Sinai Hospital
New York, NY

Tanya M. Wildes, MD, MSCI
Associate Professor of Medicine
Division of Medical Oncology
Washington University School of Medicine
660 South Euclid Avenue
St Louis, MO

Nina Shah, MD
Associate Professor
Department of Medicine
San Francisco, CA



  • Physicians, Physician Assistants, Nurse Practitioners — maximum of 3.25 AMA PRA Category 1 Credit(s)
  • Nurses — 3.25 Nursing Contact Hours
  • All other health care professionals completing this course will be issued a statement of participation.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education

Amedco LLC designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™ for physicians and 3.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Planners and Managers

  • Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant.

Disclosure of Unlabeled Use

CancerNet and Amedco require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME/CE questions, please contact: Amedco at:

For questions regarding the content, please contact: CancerNet at